BREAKING NEWS: A potential new oral drug for leishmaniasis hassuccessfully been tested in healthy humans

Full article EN (.pdf) Full article FR (.pdf) Full article DE (.pdf) Full article SP (.pdf) Full article NL...

Iran suffers from a high incidence of cutaneous leishmaniasis (CL)

Full article EN...

The Statistician’s Role in Drug Development

Full article EN...

Preclinical research demonstrates D121 outcompetes miltefosine

View full article...

TT4CL is moving forward the R&D of a new molecule, D121, for cutaneous leishmaniasis by some more preclinical research as well as a phase 1 study

View full article...

The beginnings of Oblita Therapeutic’s molecule D121

View full article...